相关实验视频

Updated: Aug 5, 2026

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

[辐射诱导的肺纤维化:新的潜在目标]

E Deutsch¹, L Meziani²

¹Département de radiothérapie, Gustave-Roussy cancer campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Radiothérapie moléculaire et innovation thérapeutique, Gustave-Roussy cancer campus, université Paris-Saclay, Inserm U1030, 114, rue Édouard-Vaillant, 94805 Villejuif, France.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

|August 18, 2023

概括

辐射诱导性肺纤维化 (RIPF) 影响了16-28%的放射后治疗 (RT) 患者. 本综述探讨了对抗RIPF的新型治疗策略,因为目前的治疗方法缺乏有效性.

科学领域:

在瘤学瘤学.
肺部病理学肺部病理学
辐射疗法辐射疗法

背景情况:

辐射诱导性肺纤维化 (RIPF) 是放射治疗 (RT) 的显著晚期并发症,发生在16-28%的患者中.
RIPF严重损害肺功能,患者的生活质量和生存率.
辐射纤维化背后的复杂信号网络需要更深入的理解,以开发有效的治疗方法.

研究的目的:

审查和讨论新兴的治疗途径,以预防和治疗RIPF.
突出需要改进治疗策略,因为目前临床选择的有效性有限.

主要方法:

对RIPF机制现有研究的文献综述.
分析潜在的新型治疗目标和策略.
讨论临床影响和未来的研究方向.

主要成果:

目前对RIPF的临床治疗已经显示出有限的疗效.
细胞和分子因素的复杂相互作用驱动辐射纤维化.
目前正在研究几个有前途的新疗法.

结论:

有效预防和治疗RIPF仍然是一个重大的临床挑战.
对辐射纤维生成机制的进一步研究至关重要.
新型治疗策略有望改善接受RT的患者的治疗结果.

关键词:

生物标志物生物标志物生物标志物生物标志物新的目标新的目标新鲜的目标是新鲜的目标.肺部有毒性肺部有毒性辐射疗法辐射疗法放射疗法 (Radiotherapy) 是一种放射疗法.肺部有毒性肺部有毒性

更多相关视频

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...